Show simple item record

dc.contributor.authorLamarca, Angela
dc.contributor.authorAsselin, Marie-Claude
dc.contributor.authorManoharan, Prakash
dc.contributor.authorMcNamara, Mairéad G
dc.contributor.authorTrigonis, I
dc.contributor.authorHubner, Richard A
dc.contributor.authorSaleem, Azeem
dc.contributor.authorValle, Juan W
dc.date.accessioned2016-02-04T09:22:27Zen
dc.date.available2016-02-04T09:22:27Zen
dc.date.issued2015-12-29en
dc.identifier.citation(18)F-FLT PET imaging of cellular proliferation in pancreatic cancer. 2015: Crit Rev Oncol Hematolen
dc.identifier.issn1879-0461en
dc.identifier.pmid26778585en
dc.identifier.doi10.1016/j.critrevonc.2015.12.014en
dc.identifier.urihttp://hdl.handle.net/10541/595566en
dc.description.abstractPancreatic ductal adenocarcinoma is known for its poor prognosis. Since the development of computerized tomography, magnetic resonance and endoscopic ultrasound, novel imaging techniques have struggled to get established in the management of patients diagnosed with pancreatic adenocarcinoma for several reasons. Thus, imaging assessment of pancreatic cancer remains a field with scope for further improvement. In contrast to cross-sectional anatomical imaging methods, molecular imaging modalities such as positron emission tomography (PET) can provide information on tumour function. Particularly, tumour proliferation may be assessed by measurement of intracellular thymidine kinase 1 (TK1) activity level using thymidine analogues radiolabelled with a positron emitter for use with PET. This approach, has been widely explored with [(18)F]-fluoro-3'-deoxy-3'-l-fluorothymidine ((18)F-FLT) PET. This manuscript reviews the rationale and physiology behind (18)F-FLT PET imaging, with special focus on pancreatic cancer and other gastrointestinal malignancies. Potential benefit and challenges of this imaging technique for diagnosis, staging and assessment of treatment response in abdominal malignancies are discussed.
dc.languageENGen
dc.language.isoenen
dc.rightsArchived with thanks to Critical reviews in oncology/hematologyen
dc.title(18)F-FLT PET imaging of cellular proliferation in pancreatic cancer.en
dc.typeArticleen
dc.contributor.departmentDept of Medical Oncology, The Christie NHS FT, Manchesteren
dc.identifier.journalCritical Reviews in Oncology/Hematologyen
html.description.abstractPancreatic ductal adenocarcinoma is known for its poor prognosis. Since the development of computerized tomography, magnetic resonance and endoscopic ultrasound, novel imaging techniques have struggled to get established in the management of patients diagnosed with pancreatic adenocarcinoma for several reasons. Thus, imaging assessment of pancreatic cancer remains a field with scope for further improvement. In contrast to cross-sectional anatomical imaging methods, molecular imaging modalities such as positron emission tomography (PET) can provide information on tumour function. Particularly, tumour proliferation may be assessed by measurement of intracellular thymidine kinase 1 (TK1) activity level using thymidine analogues radiolabelled with a positron emitter for use with PET. This approach, has been widely explored with [(18)F]-fluoro-3'-deoxy-3'-l-fluorothymidine ((18)F-FLT) PET. This manuscript reviews the rationale and physiology behind (18)F-FLT PET imaging, with special focus on pancreatic cancer and other gastrointestinal malignancies. Potential benefit and challenges of this imaging technique for diagnosis, staging and assessment of treatment response in abdominal malignancies are discussed.


Files in this item

This item appears in the following Collection(s)

Show simple item record